ReviewMolecular neurobiology2026
Targeting Histone Deacetylase 2 in Alzheimer's Disease: From Molecular Insights to Epigenetic Therapeutic Opportunities.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that leads to cognitive impairment, memory loss, and nerve cell dysfunction. Despite substantial research efforts, effective AD therapies remain limited. Histone deacetylase 2 (HDAC2) is a principal epigenetic regulator that is essential for controlling gene expression and neuronal connectivity. Recently, HDAC2 has attracted significant attention as a potential therapeutic target in AD owing to its involvement in key disease hallmarks, including neuroinflammation, Aβ accumulation, and abnormal tau phosphorylation. We have outlined and discussed the molecular insights into HDAC2 in AD and its recently emerged inhibitors. Inhibiting HDAC2 has demonstrated potential in lowering neuroinflammatory signalling and reestablishing synaptic and neuroprotective gene expression patterns in preclinical AD models. Current preclinical evidence indicates that HDAC2 may play a significant role in AD development and may represent a target for therapeutic intervention. Recent progress in HDAC2 inhibitor development offers a rationale for this approach, although further mechanistic and clinical investigations are required. Resolving the precise roles of HDAC2 dysregulation in AD and determining the utility of combination strategies remain important priorities. Whether HDAC2-targeted inhibitors can yield disease-modifying benefits in AD remains to be demonstrated in clinical studies.
Indexed as
Identifiers
42509403What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.